Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Kadcyla

(kad-SY-luh)
A drug used to treat certain patients with HER2-positive breast cancer that has already been treated with trastuzumab and a type of anticancer drug called a taxane. It is also being studied in the treatment of other types of cancer. Kadcyla contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some breast cancer cells. It also contains an anticancer drug called DM1, which may help kill cancer cells. Kadcyla is a type of antibody-drug conjugate. Also called ado-trastuzumab emtansine and T-DM1.
Search NCI's Dictionary of Cancer Terms